Annovis Bio, Inc. (ANVS) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Annovis Bio, Inc. (ANVS) closed at USD 1.02 on 2026-10-14, a change of -51.4 % over the past year, with a market capitalization of USD 44.81M.

Annovis Bio, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Annovis Bio, Inc. key figures

Previous close

USD 1.02 (2026-10-14)

1-year change

-51.4 %

Market cap

USD 44.81M

Enterprise value

USD 26.01M

P/E ratio (trailing)

-0.61

P/E ratio (forward)

-1.22

EPS (trailing)

-1.73

EPS (forward)

-0.86

PEG ratio

n/a

Price to book

-10.50

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

4.29

Employees

7

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Annovis Bio, Inc.

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Annovis Bio, Inc. and compare it with other stocks.